Latest filing published 07 Aug 2026 for Johnson & Johnson, €1.1M.
On August 6, 2026, two sales were reported at Johnson & Johnson for Elizabeth Forminard, Executive VP, General Counsel: EUR 2,083,320 and EUR 1,455,360, EUR 3,538,680 in all. They are the only two sales in the record, which holds no open-market purchase. Johnson & Johnson is the only issuer concerned, and 2026 is the busiest year in the record, with both sales falling in it.
The 12 filings, published from February 14, 2023 to August 7, 2026, are mostly option exercises (9), plus 1 grant. Activity picks up towards the end of the period: 2 filings in 2023, 3 in 2024, 2 in 2025 and then 5 in 2026. Those 5 are also the filings of the last twelve months, including the 2 sales mentioned. The publication delay is a median of 2 days.
2, 2 and 2 trades by Forminard fall within 30 days of colleagues at Johnson & Johnson, in that order. All of them in the same direction. The colleagues, in the same order: Jennifer L. Taubert, Joaquin Duato and Timothy Schmid.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 34 declarations